awmsg logo

dasatinib (Sprycel®)

Reference No. 103

Publication date:

Appraisal information

dasatinib (Sprycel®) film-coated tablet

Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 13/11/2007
AWMSG meeting date: 11/12/2007
Submission Type: Full Submission
Status: Superseded
Advice No: 1307
Ratification by Welsh Government: 16/01/2008

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA241) NICE GUIDANCE ISSUED JANUARY 2012 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Dasatinib (Sprycel®) is recommended for restricted use within NHS Wales for the treatment of adults with chronic phase chronic myeloid leukaemia (CML) and accelerated phase CML where there is resistance or intolerance to prior therapy including imatinib mesilate. The use of dasatinib for blast phase is not recommended. Resistance to imatinib is defined in accordance with the European LeukaemiaNet criteria and on completion of mutation analysis. Intolerance is defined as a patient experiencing prior grade 3/4 toxicity, in accordance with the National Cancer Institute Common Toxicity Criteria, to imatinib despite receiving the lowest clinically effective dose. Dasatinib (Sprycel®) should only be initiated by specialists experienced in the treatment of chronic myeloid leukaemia. Dasatinib (Sprycel®) is not presently recommended for shared care.
Final Appraisal Recommendation (FAR)